{
  "id": 1471833,
  "title": "Mizuho raises Amylyx stock price target to $30 on higher pricing",
  "url": "https://urgent.news/2026/08/17/mizuho-raises-amylyx-stock-price-target-to-30-on-higher-pricing",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-17T11:28:54.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/mizuho-raises-amylyx-stock-price-target-to-30-on-higher-pricing-93CH-4862773"
  },
  "original_language": "en",
  "account": "Mizuho, a prominent investment firm, has uplifted its price target on Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX) shares to $30, up from the previous $24 valuation. The firm has retained an Outperform rating, attributing the increase to the company's strong financial position and positive outlook on its lead asset, avexitide. This drug is a novel GLP-1 receptor antagonist designed to treat post-bariatric hypoglycemia, a rare condition. Mizuho's updated pricing assumptions for avexitide led to the revised target, which suggests a potential 39% upside from the current share price. The company estimates a possible $10 to $15 gain on the stock if Phase 3 LUCIDITY study results are favorable, expected by late August or early September. Mizuho highlighted that Amylyx's stock has surged 79% year-to-date, outperforming the XBI index by 29%. The firm's financial assessment reveals that Amylyx has more cash than debt on its balance sheet and liquid assets surpassing short-term obligations by a significant margin. Despite a larger-than-expected second-quarter loss, Amylyx continues to progress towards crucial Phase 3 data for avexitide, keeping investors closely watching its cash reserves and late-stage pipeline advancements.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}